Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

被引:223
|
作者
Aarsland, D
Laake, K
Larsen, JP
Janvin, C
机构
[1] Psychiat Hosp Rogaland, Sect Geriat Psychiat, N-4095 Stavanger, Norway
[2] Ulleval Hosp, Dept Geriatr Med, Oslo, Norway
[3] Cent Hosp Stavanger, Dept Neurol, Stavanger, Norway
来源
关键词
D O I
10.1136/jnnp.72.6.708
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To study the safety and efficacy of the cholinesterase inhibitor donepezil in patients with Parkinson's disease (PD) and cognitive impairment. Methods: This was a double blind, randomised and placebo controlled, crossover study in which 14 patients with PD and cognitive impairment received donepezil (5 or 10 mg per day) or matching placebo during two sequential periods lasting 10 weeks each. The primary outcome measures were the mini mental state examination (MMSE) score, the clinician's interview based impression of change plus caregiver input (CIBIC+) score, and the motor subscale of the unified Parkinson's disease rating scale (UPDRS). Results: Two patients on donepezil (14%) dropped out after one and four weeks of the first treatment period because of peripheral cholinergic side effects, otherwise the adverse effects were few and not severe. Carryover or residual effects were not observed. Parkinsonism did not increase during donepezil treatment. After 10 weeks of treatment, the mean MMSE score was increased by 2.1 (SD 2.7) points on donepezil and 0.3 (SD 3.2) points on placebo, and the CIBIC+ score was 3.3 (SD 0.9) on donepezil and 4.1 (SD 0.8) on placebo. Statistical analysis of the repeated measurements and crossover study design showed significant effects of donepezil compared with placebo for MMSE (p=0.013) and CIBIC+ (p=0.034). Five (42%) patients on donepezil and two (17%) on placebo were rated as improved on the basis of the CIBIC+ score. Conclusions: Donepezil improves cognition, and seems to be well tolerated and not to worsen parkinsonism in patients with cognitive impairment.
引用
收藏
页码:708 / 712
页数:5
相关论文
共 50 条
  • [1] Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. (vol 72, pg 708, 2002)
    Aarsland, D
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (03): : 354 - 354
  • [2] Donepezil in cognitive impairment in parkinson's disease
    Leroi, I
    Brandt, J
    Reich, SG
    Grill, S
    Thompson, R
    Lyketsos, CG
    Marsh, L
    [J]. PROCEEDINGS OF THE MENTAL DYSFUNCTIONS IN PARKINSON'S DISEASE, 2004, : 45 - 50
  • [3] Donepezil for mild cognitive impairment in Parkinson's disease
    Baik, Kyoungwon
    Kim, Seon Myeong
    Jung, Jin Ho
    Lee, Yang Hyun
    Chung, Seok Jong
    Yoo, Han Soo
    Ye, Byoung Seok
    Lee, Phil Hyu
    Sohn, Young H.
    Kang, Seung Wan
    Kang, Suk Yun
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [4] Donepezil for mild cognitive impairment in Parkinson’s disease
    Kyoungwon Baik
    Seon Myeong Kim
    Jin Ho Jung
    Yang Hyun Lee
    Seok Jong Chung
    Han Soo Yoo
    Byoung Seok Ye
    Phil Hyu Lee
    Young H. Sohn
    Seung Wan Kang
    Suk Yun Kang
    [J]. Scientific Reports, 11
  • [5] Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease
    Leroi, I
    Brandt, J
    Reich, SG
    Lyketsos, CG
    Grill, S
    Thompson, R
    Marsh, L
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2004, 19 (01) : 1 - 8
  • [6] Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study
    Ravina, B
    Putt, M
    Siderowf, A
    Farrar, JT
    Gillespie, M
    Crawley, A
    Fernandez, HH
    Trieschmann, MM
    Reichwein, S
    Simuni, T
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (07): : 934 - 939
  • [7] Incidence of Mild Cognitive Impairment and Dementia in Parkinson's Disease: The Parkinson's Disease Cognitive Impairment Study
    Nicoletti, Alessandra
    Luca, Antonina
    Baschi, Roberta
    Cicero, Calogero Edoardo
    Mostile, Giovanni
    Davi, Marco
    Pilati, Laura
    Restivo, Vincenzo
    Zappia, Mario
    Monastero, Roberto
    [J]. FRONTIERS IN AGING NEUROSCIENCE, 2019, 11
  • [8] Controlled study of decision-making and cognitive impairment in Parkinson's disease
    Pagonabarraga, Javier
    Garcia-Sanchez, Carmen
    Llebaria, Gisela
    Pascual-Sedano, Berta
    Gironell, Alexandre
    Kulisevsky, Jaime
    [J]. MOVEMENT DISORDERS, 2007, 22 (10) : 1430 - 1435
  • [9] Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: a randomised controlled trial for 2 years
    Sawada, Hideyuki
    Oeda, Tomoko
    Kohsaka, Masayuki
    Umemura, Atsushi
    Tomita, Satoshi
    Park, Kwiyoung
    Mizoguchi, Kouichi
    Matsuo, Hidenori
    Hasegawa, Kazuko
    Fujimura, Harutoshi
    Sugiyama, Hiroshi
    Nakamura, Michikazu
    Kikuchi, Seishi
    Yamamoto, Kenji
    Fukuda, Toshiaki
    Ito, Suminobu
    Goto, Masashi
    Kiyohara, Kosuke
    Kawamura, Takashi
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (12): : 1332 - 1340
  • [10] Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS)
    Roberto Monastero
    Calogero Edoardo Cicero
    Roberta Baschi
    Marco Davì
    Antonina Luca
    Vincenzo Restivo
    Chiara Zangara
    Brigida Fierro
    Mario Zappia
    Alessandra Nicoletti
    [J]. Journal of Neurology, 2018, 265 : 1050 - 1058